23 February 2026 - Launch expected second half of 2026; potential to expand access to life-changing treatment option for European patients.

Sandoz today confirmed that the European Commission has granted marketing authorisation for Ranluspec. Ranluspec is developed, manufactured and registered by Lupin and was approved based on the review of a comprehensive data package.

Read Sandoz press release